1.       Liu XJ, Yang WT, Zhou XY, Yan Q, Shi DR. [Preliminary analysis of mutations in exon 5 of IkappaBalpha gene in Hodgkin lymphoma]. Zhonghua Bing Li Xue Za Zhi. 2005;34(6):341-344.

2.       刘晓健, 李晟, 江波, 吴德沛. 乳腺癌耐药蛋白在急性髓性白血病中的表达和临床意义. 苏州大学学报:医学版. 2007;27(4):572-575.

3.       刘晓健, 杨文涛, 周晓燕, 陆洪芬, 施达仁. 霍奇金淋巴瘤IκBα基因第四外显子突变初步分析. 中华内科杂志. 2007;46(10):861-862.

4.       刘晓健, 扬文涛, 周晓燕, 陆洪芬, 施达仁. 霍奇金淋巴瘤中IκBα表达异常的研究. 苏州大学学报:医学版. 2008;28(4):591-594.

5.       刘晓健, 扬文涛, 周晓燕, 陆洪芬, 施达仁, 李进. IκBα在霍奇金淋巴瘤中的表达. Paper presented at: 全国临床肿瘤大会暨2009年csco学术年会2009.

6.       Liu X, Yu H, Yang W, Zhou X, Lu H, Shi D. Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma. Cancer Genet Cytogenet

Cancer Genetics. 2010;197(2):152-157.

7.       Zhang J, Hu X, Liu X, et al. Prognostic factors in primary gastric non-Hodgkin's lymphoma--a single-center retrospective analysis of 103 cases from China. Hepato-gastroenterology. 2010;57(101):989-996.

8.       刘晓健, 杨文涛, 周晓燕, 陆洪芬, 施达仁. 霍奇金淋巴瘤中ΙκΒα基因突变的研究. 临床与实验病理学杂志. 2010;26(2):168-172.

9.       Qiu LX, Zhang J, Li WH, et al. Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility. Mol Biol Rep. 2011;38(4):2295-2299.

10.     Yu H, Liu XJI, Li H. ALK-postive Large B-cell Lymphoma: Report of Two Cases and Review of the Literature. Journal of Cancer Science & Therapy. 2011;03(9).

11.     Liu X, Cao J, Zhang J, et al. TREATMENT OUTCOME FOR PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF 72 CASES. Paper presented at: Meeting of the Japanese-Society-Of-Medical-Oncology2012.

12.     Liu XJ, Guo Y, Fan Y, et al. Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study. Cancer Chemother Pharmacol. 2012;69(2):387-395.

13.     Yu H, Liu X, Li H, Shi D, Wang C. Primary plemorphic adenoma of bone: report of a case and literature review. Indian Journal of Pathology & Microbiology. 2012;55(2):230-232.

14.     Yu H, Zhao G, Li H, Liu X, Wang S. Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression. 2012;497(2):301-306.

15.     Zhang J, Li G, Yang H, Liu X, Cao J. Rituximab in treatment of primary gastric diffuse large B-cell lymphoma. Leukemia & lymphoma. 2012;53(11):2175-2181.

16.     Deng T, Zhang L, Liu XJ, Xu JM, Bai YX, Wang Y. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study. Medical Oncology. 2013;30(4):1-5.

17.     Xue MK. Epirubincin Does Not Lower The Risk Of Cardiac Toxicity Than Doxorubicin In Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma Grade 3 (FLG3): Results From a 398-Case Prospective Randomized Phase III Clinical Trial (NCT00854568). Blood. 2013;122:372-372.

18.     Xue K, Gu JJ, Zhang Q, et al. Elevated High Sensitivity Troponin T (HsTnT) during Front-Line Therapy with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone +/- Rituximab (CHOP+/-R) or Cyclophosphamide, Epirubicin, Vincristine and Prednisone +/- Rituximab (CEpOP+/-R) Correlates. Blood. 2014;124:3041-3041.

19.     刘晓健, 郭显志, 徐成兴, 曾艺鹏, 余明华. 组蛋白去乙酰化酶在经典型霍奇金淋巴瘤中的表达及临床意义. Paper presented at: 中国肿瘤内科进展 中国肿瘤医师教育2014.

20.     张群岭, 刘晓健, 沈维娜, 王佳琛, 洪小南, 郭晔. 聚乙二醇化重组人G-CSF在淋巴瘤化疗中预防性应用的回顾性分析. 中华血液学杂志. 2014;35(5):453-455.

21.     Guo XZ, Ye XL, Xiao WZ, et al. Downregulation of VMP1 confers aggressive properties to colorectal cancer. Oncol Rep. 2015;34(5):2557-2566.

22.     Ji D, Li Q, Cao J, et al. Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. Oncotarget. 2016;7(22):33331-33339.

23.     Liu X, Deng T, Guo X, et al. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. Hematology (Amsterdam, Netherlands). 2016:1-7.

24.     Xue K, Gu JJ, Zhang Q, et al. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. Oncotarget. 2016;7(22):32519-32531.

25.     Xue K, Ye X, Liu F, et al. Sweyjawbu expression is a predictor of ALK rearrangement status in lymphoma. Oncotarget. 2016.

26.     曹易懿, 刘倩, 奚晶, 马雷雷, 刘晓健, 栾洋. 应用Ames波动试验比较4种马兜铃酸组分的致突变作用. 癌变 畸变 突变. 2016;28(5):398-402.

27.     杜祥 王刘. 一种. 2016.

28.     郭显智, 叶小磊, 车晓航, 唐来芹, 刘晓健, 余明华. 沉默泡膜蛋白1对SW480细胞增殖与侵袭影响的研究. 中华肿瘤防治杂志. 2016;23(3):151-158.

29.     刘晓健 张. 聚乙二醇化重组人G-CSF在淋巴瘤化疗中预防性应用的回顾性分析. 2016.

30.     王奇峰, 徐清华, 陈金影, 钱琛晖, 刘晓健, 杜祥. 一种新型肿瘤组织起源分子标志物的建立与评价. 中国癌症杂志. 2016;26(10):801-812.

31.     Zhang Q, Cao J, Xue K, et al. Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma. Onco Targets Ther. 2017;10:145-151.

32.     Huang R, Zhang X, Min Z, Shadia AS, Yang S, Liu X. MGCD0103 induces apoptosis and simultaneously increases the expression of NF-kappaB and PD-L1 in classical Hodgkin's lymphoma. Exp Ther Med. 2018;16(5):3827-3834.